首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study
【24h】

The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study

机译:足够的经验治疗和时间从诱导尿路感染恢复:回顾性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Our objective was to evaluate whether patients with bacteraemic urinary tract infection ( UTI) who receive inadequate empirical therapy have worse outcomes than those with adequate therapy. This was a retrospective cohort study of patients with bacteraemic UTI. The exposure variable was adequate versus inadequate empirical antibiotic therapy ( AEAT versus IEAT) within 24 h of culture collection. Primary endpoint was time to cure. The primary analysis used propensity score models with inverse probability of treatment weights. A secondary Cox proportional hazards modelling approach was used to test the robustness of this finding, and to evaluate other patient and pathogen predictors of time to cure. Of 469 patients with bacteraemic UTI, 368 ( 78.5%) received AEAT. There was no significant difference in mortality between those receiving AEAT and those receiving IEAT ( adjusted OR 0.86, 95% CI 0.47-1.58). Receipt of AEAT had no association with time to cure ( HR 0.93, 95% CI 0.73-1.19, p 0.55) or time to normalization of individual clinical variables. Cox proportional hazards modelling revealed that longer time to cure was associated with liver disease ( HR 0.25, 95% CI 0.08e0.76, p 0.015), prior stroke ( HR 0.73, 95% CI 0.54-0.99, p 0.044), empirical receipt of piperacillin-tazobactam ( HR 0.77, 95% CI 0.59-0.99, p 0.044), qSOFA score > 1 ( HR 0.68, 95% CI 0.55-0.84, p < 0.001), and hospital-onset UTI ( HR 0.53, 95% CI 0.39-0.71, p < 0.001). In conclusion, we found no association between AEAT and time to cure for patients with bacteraemic UTI. It may be appropriate to accept a higher risk threshold when choosing empirical antibiotic regimens, even in centres with high rates of resistant uropathogens. (c) 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
机译:我们的目标是评估是否有患有经验治疗不足的诱导患者尿路感染(UTI)的患者的结果比具有足够治疗的患者。这是患有菌血症UTI患者的回顾性队列研究。暴露的变量与文化收集的24小时内相对于经验抗生素治疗(艾eeat与IEAT)相比。主要终点是治愈的时间。主要分析使用具有治疗重量的逆概率的倾向分数模型。二次Cox比例危害建模方法用于测试该发现的鲁棒性,并评估其他患者和病原体预测器来治愈。 469例患有469例菌株患者,368名(78.5%)含铝。接受含量和接受IEAT的人之间的死亡率没有显着差异(调节或0.86,95%CI 0.47-1.58)。收到艾射无关与时间结合(HR 0.93,95%CI 0.73-1.19,P 0.55)或单个临床变量的正常化时间。 Cox比例危险建模显示,较长的固化时间与肝脏疾病(HR 0.25,95%CI 0.08e0.76,p 0.015),先前中风(HR 0.73,95%CI 0.54-0.99,P 0.54-0.99,P 0.54),经验收据哌啶蛋白 - 唑唑胺(HR 0.77,95%CI 0.59-0.99,p 0.044),QSOFA得分> 1(HR 0.68,95%CI 0.55-0.84,P <0.001)和医院 - 发作UTI(HR 0.53,95% CI 0.39-0.71,P <0.001)。总之,我们发现艾eat和时间之间的治疗患者患者患者的患者。在选择经验抗生素方案时,可能适合接受更高的风险阈值,即使在具有高耐药尿素率的中心的中心。 (c)2019年欧洲临床微生物学和传染病学会。 elsevier有限公司出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号